XHKG
2652
Market cap217mUSD
Oct 28, Last price
5.64HKD
1D
0.18%
1Q
-64.08%
IPO
-82.97%
Name
CF PharmTech Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases. In addition, it develops therapeutic products for respiratory and other diseases, such as inhalation spray and aerosol, dry powder inhaler, nebulization, nasal spray products, as well as liposomes. Further, the company provides CDMO/CMO technical services. CF PharmTech, Inc. was formerly known as Suzhou CF PharmTech Co., Ltd. CF PharmTech, Inc. was founded in 2007 and is based in Suzhou, China.
Key people
Bill Wenqing Liang
Executive Chairman of the Board, Chief Executive Officer
Qi Li
Chief Operating Officer, Executive Director and Dean of Pharmaceutical Research Institute
Bovet Li Li
Chief Scientific Officer, Executive Director
Yuyu Zhu
Deputy General Manager, Executive Director, Joint Company Secretary
Cheuk Ting Chu
Joint Company Secretary · since 2025
Lei Cai
Non-Executive Director · since 2024
Penghui Chen
Non-Executive Director · since 2024
Hua Yi
Non-Executive Director · since 2024
Jian Jin
Non-Executive Independent Director · since 2024
Lijuan Wang
Non-Executive Independent Director · since 2024
Shirong Wei
Non-Executive Independent Director · since 2024
Valuation
No data to show